EBV+ PTLD IS AN UNPREDICTABLE THREAT FOR TRANSPLANT RECIPIENTS
Post-transplant lymphoproliferative disease (PTLD) is a lymphoid and/or plasmacytic proliferation that occurs as a result of immunosuppression in a setting of solid organ or allogeneic hematopoietic cell transplantation. PTLD can be Epstein-Barr virus (EBV) positive or EBV negative.1
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute, and potentially life-threatening lymphoma that presents challenges in the management of transplant patients.2 Staying connected to the latest scientific information, treatment guidelines, and useful resources about EBV+ PTLD can help you provide the best possible care for your patients.
Learn more about:
Post-transplant primary infection or viral reactivation
in HCT Patients
1. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183. 2. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Eng J Med. 2018;378(6):549-562.